These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 18451235)

  • 1. The effect of ketoconazole on the pharmacokinetics and pharmacodynamics of ixabepilone: a first in class epothilone B analogue in late-phase clinical development.
    Goel S; Cohen M; Cömezoglu SN; Perrin L; André F; Jayabalan D; Iacono L; Comprelli A; Ly VT; Zhang D; Xu C; Humphreys WG; McDaid H; Goldberg G; Horwitz SB; Mani S
    Clin Cancer Res; 2008 May; 14(9):2701-9. PubMed ID: 18451235
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I study of the novel epothilone analog ixabepilone (BMS-247550) in patients with advanced solid tumors and lymphomas.
    Aghajanian C; Burris HA; Jones S; Spriggs DR; Cohen MB; Peck R; Sabbatini P; Hensley ML; Greco FA; Dupont J; O'Connor OA
    J Clin Oncol; 2007 Mar; 25(9):1082-8. PubMed ID: 17261851
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peripheral blood mononuclear and tumor cell pharmacodynamics of the novel epothilone B analogue, ixabepilone.
    Mani S; McDaid HM; Grossman A; Muggia F; Goel S; Griffin T; Colevas D; Horwitz SB; Egorin MJ
    Ann Oncol; 2007 Jan; 18(1):190-195. PubMed ID: 17018704
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A single-center, open-label, one-sequence study of dalcetrapib coadministered with ketoconazole, and an in vitro study of the S-methyl metabolite of dalcetrapib.
    Derks M; Fowler S; Kuhlmann O
    Clin Ther; 2009 Mar; 31(3):586-99. PubMed ID: 19393849
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ixabepilone for the treatment of solid tumors: a review of clinical data.
    Denduluri N; Swain SM
    Expert Opin Investig Drugs; 2008 Mar; 17(3):423-35. PubMed ID: 18321240
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proactive management of adverse events maintains the clinical benefit of ixabepilone.
    Yardley DA
    Oncologist; 2009 May; 14(5):448-55. PubMed ID: 19411315
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of cytochrome P450 3A4 inducer and inhibitor on the pharmacokinetics of trabectedin in patients with advanced malignancies: open-label, multicenter studies.
    Machiels JP; Staddon A; Herremans C; Keung C; Bernard A; Phelps C; Khokhar NZ; Knoblauch R; Parekh TV; Dirix L; Sharma S
    Cancer Chemother Pharmacol; 2014 Oct; 74(4):729-37. PubMed ID: 25100135
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I clinical study of the novel epothilone B analogue BMS-310705 given on a weekly schedule.
    Sessa C; Perotti A; Lladò A; Cresta S; Capri G; Voi M; Marsoni S; Corradino I; Gianni L
    Ann Oncol; 2007 Sep; 18(9):1548-53. PubMed ID: 17761711
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The optimal therapeutic use of ixabepilone in patients with locally advanced or metastatic breast cancer.
    Boehnke Michaud L
    J Oncol Pharm Pract; 2009 Jun; 15(2):95-106. PubMed ID: 19171553
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Phase I Clinical, Pharmacokinetic, and Pharmacodynamic Study of Weekly or Every Three Week Ixabepilone and Daily Sunitinib in Patients with Advanced Solid Tumors.
    Montero AJ; Kwon D; Flores A; Kovacs K; Trent JC; Benedetto P; Rocha-Lima C; Merchan JR
    Clin Cancer Res; 2016 Jul; 22(13):3209-17. PubMed ID: 26864210
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I clinical and pharmacokinetic study of 3-weekly, 3-h infusion of ixabepilone (BMS-247550), an epothilone B analog, in Japanese patients with refractory solid tumors.
    Shimizu T; Yamamoto N; Yamada Y; Fujisaka Y; Yamada K; Fujiwara Y; Takayama K; Tokudome T; Klimovsky J; Tamura T
    Cancer Chemother Pharmacol; 2008 Apr; 61(5):751-8. PubMed ID: 17594093
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ixabepilone-associated peripheral neuropathy: data from across the phase II and III clinical trials.
    Vahdat LT; Thomas ES; Roché HH; Hortobagyi GN; Sparano JA; Yelle L; Fornier MN; Martín M; Bunnell CA; Mukhopadhyay P; Peck RA; Perez EA
    Support Care Cancer; 2012 Nov; 20(11):2661-8. PubMed ID: 22382588
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of the CYP3A inhibitor ketoconazole on the pharmacokinetics and pharmacodynamics of bortezomib in patients with advanced solid tumors: a prospective, multicenter, open-label, randomized, two-way crossover drug-drug interaction study.
    Venkatakrishnan K; Rader M; Ramanathan RK; Ramalingam S; Chen E; Riordan W; Trepicchio W; Cooper M; Karol M; von Moltke L; Neuwirth R; Egorin M; Chatta G
    Clin Ther; 2009; 31 Pt 2():2444-58. PubMed ID: 20110052
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ixabepilone: a novel microtubule inhibitor for the treatment of locally advanced or metastatic breast cancer.
    Steinberg M
    Clin Ther; 2008 Sep; 30(9):1590-617. PubMed ID: 18840366
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of cytochrome P450 3A4 inhibitor ketoconazole on risperidone pharmacokinetics in healthy volunteers.
    Mahatthanatrakul W; Sriwiriyajan S; Ridtitid W; Boonleang J; Wongnawa M; Rujimamahasan N; Pipatrattanaseree W
    J Clin Pharm Ther; 2012 Apr; 37(2):221-5. PubMed ID: 21518375
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic (PK) drug interaction studies of cabozantinib: Effect of CYP3A inducer rifampin and inhibitor ketoconazole on cabozantinib plasma PK and effect of cabozantinib on CYP2C8 probe substrate rosiglitazone plasma PK.
    Nguyen L; Holland J; Miles D; Engel C; Benrimoh N; O'Reilly T; Lacy S
    J Clin Pharmacol; 2015 Sep; 55(9):1012-23. PubMed ID: 25854986
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of ketoconazole and esomeprazole on the pharmacokinetics of pazopanib in patients with solid tumors.
    Tan AR; Gibbon DG; Stein MN; Lindquist D; Edenfield JW; Martin JC; Gregory C; Suttle AB; Tada H; Botbyl J; Stephenson JJ
    Cancer Chemother Pharmacol; 2013 Jun; 71(6):1635-43. PubMed ID: 23636448
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of ketoconazole or rifampin on the pharmacokinetics of tivozanib hydrochloride, a vascular endothelial growth factor receptor tyrosine kinase inhibitor.
    Cotreau MM; Siebers NM; Miller J; Strahs AL; Slichenmyer W
    Clin Pharmacol Drug Dev; 2015 Mar; 4(2):137-42. PubMed ID: 27128217
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical efficacy spectrum and pharmacokinetics of ixabepilone.
    Lee FY; Smykla R; Johnston K; Menard K; McGlinchey K; Peterson RW; Wiebesiek A; Vite G; Fairchild CR; Kramer R
    Cancer Chemother Pharmacol; 2009 Jan; 63(2):201-12. PubMed ID: 18350296
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of cytochrome P450 3A modulators ketoconazole and carbamazepine on quetiapine pharmacokinetics.
    Grimm SW; Richtand NM; Winter HR; Stams KR; Reele SB
    Br J Clin Pharmacol; 2006 Jan; 61(1):58-69. PubMed ID: 16390352
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.